SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Indications -- Hepatitis
An SI Board Since March 2001
Posts SubjectMarks Bans
312 28 0
Emcee:  tuck Type:  Unmoderated
Introduction Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
187Overview of HCV drug development space from Signals: signalsmag.com Cheers, Ttuck-6/30/2007
186Viread update in HBV: investorshub.comDewDiligence_on_SI-6/26/2007
185A handy HCV graphic (from a recent VRUS webcast): investorshub.comDewDiligence_on_SI-6/8/2007
184GILD’s Viread works in HBV: investorshub.comDewDiligence_on_SI-6/6/2007
183You may have to register for the VRUS webcast at investor.pharmasset.com in ordeDewDiligence_on_SI-5/31/2007
182VRUS webcast slides from BofA: veracast.com This company probably ought to haveDewDiligence_on_SI-5/31/2007
181<b> HBV Patients’ Understanding of Infection and Treatment Deficient, AccoDewDiligence_on_SI-5/24/2007
180SVR really is tantamount to a cure for HCV. Roche reported today on a long-termDewDiligence_on_SI-5/21/2007
179"THE" binding site? Don't hold your breath. In five years, it wiscaram(o)uche-5/15/2007
178[Hep C prophylaxis with a modified adenoviral vaccine] jvi.asm.org Full text ftuck-5/13/2007
177HCV infection associated with development of non-Hodgkin lymphoma Posted: May 8zeta1961-5/13/2007
176<b> Celera Publishes Proprietary Genetic Assay as Predictor of Cirrhosis iDewDiligence_on_SI-4/27/2007
175<b> Pharmasset IPO’s at Low End of Range </b>($9/sh) <i>[ThisDewDiligence_on_SI-4/26/2007
174U.S. HBV market is expanding rapidly: investorshub.comDewDiligence_on_SI-4/18/2007
173HCV combination treatment with VX-950 (VRTX), ACH-806 (GILD/ACHN), and NM107 (IDDewDiligence_on_SI-4/13/2007
172[ApoB-100 as target in VLDL inhibition in HCV therapy] It is possible ISIS 3010tuck-4/9/2007
171[Very low-density lipoproteins at HCV targets] >>Hepatitis C virus productuck-4/9/2007
170Claudin-1 as a new target for entry inhibition in HCV >>Nature. 2007 Feb tuck-4/9/2007
169EASL Scientific Programme: titles of oral sessions and posters are available. Ltnsaf-4/6/2007
168Baraclude letter to doctors re HBV-HIV co-infection: fda.govDewDiligence_on_SI-2/24/2007
167Locteron for Treatment-Naïve HCV Enters Phase-2: investorshub.comDewDiligence_on_SI-1/30/2007
166<b> ZGEN Enters Phase-1 with Peg-Interferon <i>Lambda</i> for DewDiligence_on_SI-1/30/2007
165VX-950 has come down to Earth: investorshub.comDewDiligence_on_SI-12/13/2006
164Proportions of HCV Genotypes by Country: investorshub.comDewDiligence_on_SI-12/11/2006
163<HCV> Parking..a nice summary of current standard of care in this week'zeta1961-12/8/2006
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News